Tasos Konidaris - 03 Mar 2026 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role
Executive Vice President & CFO
Signature
/s/ Denis Butkovic, Attorney-in-Fact
Issuer symbol
AMRX
Transactions as of
03 Mar 2026
Net transactions value
$0
Form type
4
Filing time
05 Mar 2026, 16:31:57 UTC
Previous filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Konidaris Tasos Executive Vice President & CFO C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER /s/ Denis Butkovic, Attorney-in-Fact 05 Mar 2026 0001320982

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMRX Class A Common Stock Options Exercise +45,290 +37% 167,442 03 Mar 2026 Direct F1, F2
transaction AMRX Class A Common Stock Tax liability -16,182 -9.7% $13.31* 151,260 03 Mar 2026 Direct F3
transaction AMRX Class A Common Stock Options Exercise +57,339 +38% 208,599 03 Mar 2026 Direct F1, F2
transaction AMRX Class A Common Stock Tax liability -24,251 -12% $13.31* 184,348 03 Mar 2026 Direct F3
transaction AMRX Class A Common Stock Options Exercise +28,538 +15% 212,886 03 Mar 2026 Direct F1, F2
transaction AMRX Class A Common Stock Tax liability -14,298 -6.7% $13.31* 198,588 03 Mar 2026 Direct F3
transaction AMRX Class A Common Stock Options Exercise +458,716 +231% 657,304 03 Mar 2026 Direct F4
transaction AMRX Class A Common Stock Tax liability -229,817 -35% $13.31* 427,487 03 Mar 2026 Direct F5
transaction AMRX Class A Common Stock Options Exercise +43,982 +10% 471,469 04 Mar 2026 Direct F1, F2
transaction AMRX Class A Common Stock Tax liability -22,035 -4.7% $13.30* 449,434 04 Mar 2026 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMRX Restricted Stock Units Options Exercise -45,290 -100% $0.000000* 0 03 Mar 2026 Class A Common Stock 45,290 Direct F2, F6
transaction AMRX Restricted Stock Units Options Exercise -57,339 -50% $0.000000* 57,340 03 Mar 2026 Class A Common Stock 57,339 Direct F2, F7
transaction AMRX Restricted Stock Units Options Exercise -28,538 -25% $0.000000* 85,617 03 Mar 2026 Class A Common Stock 28,538 Direct F2, F8
transaction AMRX Performance-Based Restricted Stock Units Options Exercise -458,716 -100% $0.000000* 0 03 Mar 2026 Class A Common Stock 458,716 Direct F4
transaction AMRX Restricted Stock Units Options Exercise -49,982 -36% $0.000000* 87,963 04 Mar 2026 Class A Common Stock 49,982 Direct F2, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3 Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4 Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.
F5 Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units.
F6 On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F7 On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F8 On March 3, 2025, the reporting person was granted 114,155 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F9 On March 4, 2024, the reporting person was granted 175,926 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.